Blair William & Co. IL Has $43.29 Million Stock Holdings in Eli Lilly And Co (NYSE:LLY)

Share on StockTwits

Blair William & Co. IL cut its stake in Eli Lilly And Co (NYSE:LLY) by 7.0% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 312,042 shares of the company’s stock after selling 23,412 shares during the period. Blair William & Co. IL’s holdings in Eli Lilly And Co were worth $43,286,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. BlackRock Inc. raised its holdings in Eli Lilly And Co by 5.6% in the 1st quarter. BlackRock Inc. now owns 64,299,477 shares of the company’s stock valued at $8,919,623,000 after acquiring an additional 3,420,265 shares in the last quarter. Capital International Investors raised its holdings in Eli Lilly And Co by 3.6% in the 4th quarter. Capital International Investors now owns 26,055,933 shares of the company’s stock valued at $3,424,531,000 after acquiring an additional 910,672 shares in the last quarter. FMR LLC raised its holdings in Eli Lilly And Co by 6.7% in the 4th quarter. FMR LLC now owns 14,235,227 shares of the company’s stock valued at $1,870,935,000 after acquiring an additional 888,413 shares in the last quarter. Geode Capital Management LLC raised its holdings in Eli Lilly And Co by 1.9% in the 4th quarter. Geode Capital Management LLC now owns 12,377,007 shares of the company’s stock valued at $1,623,438,000 after acquiring an additional 226,620 shares in the last quarter. Finally, Jennison Associates LLC raised its holdings in Eli Lilly And Co by 125.9% in the 1st quarter. Jennison Associates LLC now owns 10,192,052 shares of the company’s stock valued at $1,413,841,000 after acquiring an additional 5,679,574 shares in the last quarter. 77.98% of the stock is owned by hedge funds and other institutional investors.

In related news, major shareholder Lilly Endowment Inc sold 12,663 shares of the company’s stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $163.60, for a total transaction of $2,071,666.80. Following the sale, the insider now owns 112,197,641 shares in the company, valued at approximately $18,355,534,067.60. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Stephen F. Fry sold 14,657 shares of the company’s stock in a transaction dated Monday, March 30th. The shares were sold at an average price of $134.30, for a total value of $1,968,435.10. Following the sale, the senior vice president now owns 110,572 shares in the company, valued at approximately $14,849,819.60. The disclosure for this sale can be found here. Insiders sold a total of 906,320 shares of company stock worth $132,984,238 in the last quarter. Corporate insiders own 0.09% of the company’s stock.

LLY stock traded down $1.12 during midday trading on Friday, reaching $151.16. 2,322,495 shares of the stock were exchanged, compared to its average volume of 2,875,585. The company has a fifty day moving average price of $152.85 and a 200 day moving average price of $136.00. Eli Lilly And Co has a 52 week low of $101.36 and a 52 week high of $164.90. The stock has a market capitalization of $145.65 billion, a PE ratio of 24.99, a P/E/G ratio of 1.82 and a beta of 0.25. The company has a debt-to-equity ratio of 4.37, a current ratio of 1.11 and a quick ratio of 0.86.

Eli Lilly And Co (NYSE:LLY) last released its quarterly earnings results on Thursday, April 23rd. The company reported $1.75 EPS for the quarter, beating analysts’ consensus estimates of $1.48 by $0.27. Eli Lilly And Co had a return on equity of 194.18% and a net margin of 23.97%. The firm had revenue of $5.86 billion for the quarter, compared to analyst estimates of $5.48 billion. During the same quarter in the previous year, the company posted $1.33 EPS. The business’s revenue was up 15.1% on a year-over-year basis. As a group, analysts anticipate that Eli Lilly And Co will post 6.81 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be given a $0.74 dividend. The ex-dividend date is Thursday, May 14th. This represents a $2.96 dividend on an annualized basis and a dividend yield of 1.96%. Eli Lilly And Co’s dividend payout ratio (DPR) is presently 49.01%.

A number of equities analysts have recently commented on LLY shares. Zacks Investment Research lowered their price target on Eli Lilly And Co to $156.00 in a report on Wednesday, April 29th. Cantor Fitzgerald boosted their price target on Eli Lilly And Co from $156.00 to $185.00 and gave the stock an “overweight” rating in a report on Friday, April 24th. Goldman Sachs Group raised Eli Lilly And Co from a “buy” rating to a “conviction-buy” rating and set a $168.00 price target for the company in a report on Wednesday, March 11th. UBS Group cut Eli Lilly And Co from a “buy” rating to a “neutral” rating and boosted their price target for the stock from $157.00 to $158.00 in a report on Monday, April 20th. Finally, Barclays started coverage on Eli Lilly And Co in a report on Thursday, February 27th. They set an “overweight” rating for the company. Four analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. Eli Lilly And Co has an average rating of “Buy” and an average target price of $158.64.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Featured Article: Understanding the Price to Earnings Ratio (PE)

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply